il-15 agonist n-803 Search Results


avelumab n-803  (NantCell Inc)
90
NantCell Inc avelumab n-803
Top left, in red: NK cells recognize tumor targets that lack MHC, as this prevents the inhibitory response mediated by KIR. Several tumors down-regulate MHC in response to T cell immune pressure. The same pathway does not become activated in the setting of allogeneic NK cells and is only engaged when NK cell effectors recognize self MHC. Bottom, in blue: NK cell activating receptor ligands are expressed by numerous malignancies [45-60,62,242-247], and these tumors engage NK-activating receptors, some of which associate with ITAM-containing DAP10 and DAP12 to mediate NK cell activation via proteins such as Vav1 and PLCγ2. Top right, in green: NK cells are the principal effectors of ADCC, mediating tumor lysis in settings when antibodies targeting overexpressed surface targets are used. Various antibodies have been developed to recruit ADCC against tumor cells bearing targets such as Her2, CD20, EGFR, and/or CD52. These antibodies bind to the <t>CD16</t> receptor, which, in turn, is associated with ITAM-containing proteins such as the TCRζ chain–leading to NK cell activation.
Avelumab N 803, supplied by NantCell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/avelumab n-803/product/NantCell Inc
Average 90 stars, based on 1 article reviews
avelumab n-803 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
il-15 superagonist n-803  (SMAC Corp)
90
SMAC Corp il-15 superagonist n-803
Top left, in red: NK cells recognize tumor targets that lack MHC, as this prevents the inhibitory response mediated by KIR. Several tumors down-regulate MHC in response to T cell immune pressure. The same pathway does not become activated in the setting of allogeneic NK cells and is only engaged when NK cell effectors recognize self MHC. Bottom, in blue: NK cell activating receptor ligands are expressed by numerous malignancies [45-60,62,242-247], and these tumors engage NK-activating receptors, some of which associate with ITAM-containing DAP10 and DAP12 to mediate NK cell activation via proteins such as Vav1 and PLCγ2. Top right, in green: NK cells are the principal effectors of ADCC, mediating tumor lysis in settings when antibodies targeting overexpressed surface targets are used. Various antibodies have been developed to recruit ADCC against tumor cells bearing targets such as Her2, CD20, EGFR, and/or CD52. These antibodies bind to the <t>CD16</t> receptor, which, in turn, is associated with ITAM-containing proteins such as the TCRζ chain–leading to NK cell activation.
Il 15 Superagonist N 803, supplied by SMAC Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il-15 superagonist n-803/product/SMAC Corp
Average 90 stars, based on 1 article reviews
il-15 superagonist n-803 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Top left, in red: NK cells recognize tumor targets that lack MHC, as this prevents the inhibitory response mediated by KIR. Several tumors down-regulate MHC in response to T cell immune pressure. The same pathway does not become activated in the setting of allogeneic NK cells and is only engaged when NK cell effectors recognize self MHC. Bottom, in blue: NK cell activating receptor ligands are expressed by numerous malignancies [45-60,62,242-247], and these tumors engage NK-activating receptors, some of which associate with ITAM-containing DAP10 and DAP12 to mediate NK cell activation via proteins such as Vav1 and PLCγ2. Top right, in green: NK cells are the principal effectors of ADCC, mediating tumor lysis in settings when antibodies targeting overexpressed surface targets are used. Various antibodies have been developed to recruit ADCC against tumor cells bearing targets such as Her2, CD20, EGFR, and/or CD52. These antibodies bind to the CD16 receptor, which, in turn, is associated with ITAM-containing proteins such as the TCRζ chain–leading to NK cell activation.

Journal: Transplantation and cellular therapy

Article Title: NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations

doi: 10.1016/j.bbmt.2020.09.030

Figure Lengend Snippet: Top left, in red: NK cells recognize tumor targets that lack MHC, as this prevents the inhibitory response mediated by KIR. Several tumors down-regulate MHC in response to T cell immune pressure. The same pathway does not become activated in the setting of allogeneic NK cells and is only engaged when NK cell effectors recognize self MHC. Bottom, in blue: NK cell activating receptor ligands are expressed by numerous malignancies [45-60,62,242-247], and these tumors engage NK-activating receptors, some of which associate with ITAM-containing DAP10 and DAP12 to mediate NK cell activation via proteins such as Vav1 and PLCγ2. Top right, in green: NK cells are the principal effectors of ADCC, mediating tumor lysis in settings when antibodies targeting overexpressed surface targets are used. Various antibodies have been developed to recruit ADCC against tumor cells bearing targets such as Her2, CD20, EGFR, and/or CD52. These antibodies bind to the CD16 receptor, which, in turn, is associated with ITAM-containing proteins such as the TCRζ chain–leading to NK cell activation.

Article Snippet: {"type":"clinical-trial","attrs":{"text":"NCT03853317","term_id":"NCT03853317"}} NCT03853317 , NantKwest, Inc.; NantCell, Inc. , NK92 cell line modified to express IL-2 and CD16 (haNK) Avelumab N-803 , Merkel cell carcinoma.

Techniques: Activation Assay, Lysis